Panacur® (fenbendazole) Paste 10% (100 mg/g) Equine Dewormer

DESCRIPTION
Panacur® (fenbendazole) Paste 10% contains the active anthelmintic, fenbendazole. The chemical name of fenbendazole is methyl 5-(phenylthio)-2-benzimidazole carbamate.

The chemical structure is:

```
\begin{center}
\includegraphics[width=0.5\textwidth]{fenbendazole.png}
\end{center}
```

Each gram of Panacur® (fenbendazole) Paste 10% contains 100 mg of fenbendazole and is flavored with artificial apple-cinnamon liquid.

ACTIONS
The antiparasitic action of Panacur® (fenbendazole) Paste 10% is believed to be due to the inhibition of energy metabolism in the parasite.

INDICATIONS
Panacur® (fenbendazole) Paste 10% is indicated for the control of large strongyles (Strongylus edentatus, S. equinus, S. vulgaris), encysted early third stage (hypobiotic), late third stage and fourth stage cyathostome larvae, small strongyles, pinworms (Oxyuris equi), ascarids (Parascaris equorum), and arteritis caused by fourth stage larvae of Strongylus vulgaris in horses.

Panacur® (fenbendazole) Paste 10% is approved for use concomitantly with an approved form of trichlorfon. Trichlorfon is approved for the treatment of stomach bots (Gasterophilus spp.) in horses. Refer to the manufacturer's label for directions for use and cautions for trichlorfon.

PRECAUTIONS
Side effects associated with Panacur® (fenbendazole) Paste 10% could not be established in well-controlled safety studies in horses with single doses as high as 454 mg/lb (1,000 mg/kg) and 15 consecutive daily doses of 22.7 mg/lb (50 mg/kg). Particularly with higher doses, the lethal action of fenbendazole may cause the release of antigens by the dying parasites. This phenomenon may result in either a local or systemic hypersensitive reaction. As with any drug, these reactions should be treated symptomatically.

Panacur® (fenbendazole) Paste 10% has been evaluated for safety in pregnant mares during all stages of
gestation with doses as high as 11.4 mg/lb (25 mg/kg) and in stallions with doses as high as 11.4 mg/lb (25 mg/kg). No adverse effects on reproductivity were detected. The recommended dose for control of 4th stage larvae of *Strongylus vulgaris*, 4.6 mg/lb (10 mg/kg) daily for 5 consecutive days, has not been evaluated for safety in stallions or pregnant mares.

**Internal Parasites**

Regular deworming at intervals of six to eight weeks may be required due to the possibility of reinfection.

**Migrating Tissue Parasites**

In the case of 4th stage larvae of *Strongylus vulgaris*, treatment and retreatment should be based on the life cycle and the epidemiology. Treatment should be initiated in the spring and repeated in the fall after a six month interval.

**Optimum Deworming Program for control of *S. vulgaris***

Optimum reduction of *S. vulgaris* infections is achieved by reducing the infectivity of the pastures. When horses are running on pasture, in temperate North America, maximum pasture infectivity occurs in October–December. If horses are removed from those pastures in January, pasture infectivity will decline to zero by July 1. Egg production of *S. vulgaris* is minimal from January through April, peaking in August and declining to minimal values in December.

**Recommended Deworming Program**

**December 1, February 1, April 1, June 1, August 1, October 1.**

The two treatments that are in bold type are the recommended periods when the 5 day treatment regimen for the control of the migrating larvae of *S. vulgaris* should be performed.

**For other areas in the world, retreatment periods for the migrating larvae of *S. vulgaris* may be different; consult with your veterinarian.**

**CAUTIONS**

*Keep this and all medication out of the reach of children.*

When using Panacur® (fenbendazole) Paste 10% concomitantly with trichlorfon, refer to the manufacturer's labels for use and cautions for trichlorfon.

**WARNING**

*Do not use in horses intended for human consumption*

**DOSAGE**

Panacur® (fenbendazole) Paste 10% is administered orally at a rate of 2.3 mg/lb (5 mg/kg) for the control of large strongyles, small strongyles, and pinworms. One syringe will deworm a 1,100 lb horse. For foals and weanlings (less than 18 months of age) where ascarids are a common problem, the recommended dose is 4.6 mg/lb (10 mg/kg); one syringe will deworm a 550 lb horse.

For control of encysted early third stage (hypobiotic), late third stage and fourth stage cyathostome larvae, and fourth stage larvae of *Strongylus vulgaris*, the recommended dose is 4.6 mg/lb (10 mg/kg) daily for 5 consecutive days; administer one syringe for each 550 lbs body weight per day.

**SEE PRECAUTIONS FOR RETREATMENT RECOMMENDATIONS.**
DIRECTIONS FOR USE
1. Determine the weight of the horse.
2. Remove syringe tip.
3. Turn the dial ring until the edge of the ring nearest the tip lines up with zero.
4. Depress plunger to advance paste to tip.
5. Now set the dial ring at the graduation nearest the weight of the horse (do not underdose).
6. Horse's mouth must be free of food.
7. Insert nozzle of syringe through the interdental space and deposit the paste on the back of the tongue by depressing the plunger.

HOW SUPPLIED
Panacur® (fenbendazole) Paste 10% Equine Dewormer is supplied in 25 g syringes.

Store at or below 25°C (77°F).

CONSULT YOUR VETERINARIAN FOR ASSISTANCE IN THE DIAGNOSIS, TREATMENT AND CONTROL OF PARASITISM.

Made in France
Distributed by:
Intervet Inc.
Millsboro, DE 19966
NADA #120-648, Approved by FDA
For use in animals only.

PRINCIPAL DISPLAY PANEL - 100 mg/g Syringe Carton

intervet
panacur®
(fenbendazole)
Equine Dewormer
Equine Dewormer
25 gram Paste 10%
(100 mg/g)
PRINCIPAL DISPLAY PANEL - 100 mg/g Syringe Label

intervet

panacur®
(fenbendazole)

Equine Dewormer 57 gram Paste 10% (100 mg/g)

FOR USE IN ANIMALS ONLY.

Net Wt. 57 g (2.01 oz)

WARNING: DO NOT USE IN HORSES INTENDED FOR HUMAN CONSUMPTION.

DIRECTIONS:
1. Determine the weight of the horse.
2. Remove syringe tip.
3. Turn the dial ring until the edge of the ring nearest the tip lines up with zero.
4. Depress plunger to advance paste to tip.
5. Now set the dial ring at the graduation nearest the weight of the horse (do not underdose).
6. Horse's mouth should be free of food.
7. Insert nozzle of syringe through the interdental space and deposit the paste on the back of the tongue by depressing the plunger.

The contents of one syringe will deworm two 1,250 lb (568 kg) horses at the standard dosage rate of 2.3 mg/lb (5 mg/kg). Refer to the carton for dosage and full directions for use and for treatment of ascarids, encysted early third stage (hypobiotic), late third stage and fourth stage cyathostome larvae and 4th stage larvae of Strongylus vulgaris as well as for concomitant use with trichlorfon.

CONSULT YOUR VETERINARIAN FOR ASSISTANCE IN THE DIAGNOSIS, TREATMENT AND CONTROL OF PARASITISM.

Each syringe contains 5.7 g of fenbendazole.

Keep this and all medication out of the reach of children.

Store at or below 25°C (77°F).

Manufactured by: DPT Laboratories,
San Antonio, TX 78215

Panacur is the property of Intervet International B.V. or affiliated companies or licensors and is protected by copyrights, trademark and other
FOR USE IN ANIMALS ONLY
WARNING: DO NOT USE IN HORSES INTENDED FOR
HUMAN CONSUMPTION
Net Wt. 57 g (2.01 oz)

DIRECTIONS:
1. Determine the weight of the horse.
2. Remove syringe tip.
3. Turn the dial ring until the edge of the ring nearest the tip lines up with zero.
4. Depress plunger to advance paste to tip.
5. Now set the dial ring at the graduation nearest the weight of the horse (do not underdose).
6. Horse’s mouth should be free of food.
7. Insert nozzle of syringe through the interdental space and deposit the paste on the back of the tongue by depressing the plunger.

The contents of one syringe will deworm two 1,250 lb (568 kg) horses at the standard dosage rate of 2.3 mg/lb (5 mg/kg). Refer to the carton for dosage and full directions for use and for treatment of ascarids, encysted early third stage (hypobiotic), late third stage and fourth stage cyathostome larvae and 4th stage larvae of *Strongylus vulgaris* as well as for concomitant use with trichlorfon.

CONSULT YOUR VETERINARIAN FOR ASSISTANCE IN THE DIAGNOSIS, TREATMENT AND CONTROL OF PARASITISM. Each syringe contains 5.7 g of fenbendazole.

Keep this and all medication out of the reach of children. Store at or below 25°C (77°F).
Made in France
Distributed by:
Intervet Inc., Millsboro, DE 19966
NADA # 120-648, Approved by FDA

Lot:
Exp.
PANACUR fenbendazole paste

Product Information

Product Type | OTC ANIMAL DRUG
Route of Administration | ORAL

Active Ingredient/Active Moiety

<table>
<thead>
<tr>
<th>Ingredient Name</th>
<th>Basis of Strength</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fenbendazole (UNII: 621BVT9M36) (Fenbendazole - UNII:621BVT9M36)</td>
<td>Fenbendazole</td>
<td>100 mg in 1 g</td>
</tr>
</tbody>
</table>

Inactive Ingredients

<table>
<thead>
<tr>
<th>Ingredient Name</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carbomer Homopolymer Type B (Allyl Pentaerythritol Crosslinked) (UNII: HHT01ZNK31)</td>
<td></td>
</tr>
<tr>
<td>Propylene Glycol (UNII: 6DC9Q167V3)</td>
<td></td>
</tr>
<tr>
<td>Glycerin (UNII: PDC6A3C0OX)</td>
<td></td>
</tr>
<tr>
<td>Sorbitol (UNII: 506T60A25R)</td>
<td></td>
</tr>
<tr>
<td>Water (UNII: 059QF0KO0R)</td>
<td></td>
</tr>
<tr>
<td>Sodium Hydroxide (UNII: 55X04QC32I)</td>
<td></td>
</tr>
<tr>
<td>Methylparaben (UNII: A2I8C7HI9T)</td>
<td></td>
</tr>
<tr>
<td>Propylparaben (UNII: Z8IX2SC1OH)</td>
<td></td>
</tr>
</tbody>
</table>

Product Characteristics

Color | Score
Shape | Size
Flavor | APPLE, CINNAMON
Contains |

Packaging

<table>
<thead>
<tr>
<th>#</th>
<th>Item Code</th>
<th>Package Description</th>
<th>Marketing Start Date</th>
<th>Marketing End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>NDC:57926-081-44</td>
<td>1 in 1 CARTON</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td></td>
<td>25 g in 1 SYRINGE, PLASTIC</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Marketing Information

Marketing Category | Application Number or Monograph Citation | Marketing Start Date | Marketing End Date
NADA | NADA120648 | 05/10/2010 |
# Product Information

<table>
<thead>
<tr>
<th>Product Type</th>
<th>OTC ANIMAL DRUG</th>
<th>Item Code (Source)</th>
<th>NDC:57926-082</th>
</tr>
</thead>
<tbody>
<tr>
<td>Route of Administration</td>
<td>ORAL</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

## Active Ingredient/Active Moiety

<table>
<thead>
<tr>
<th>Ingredient Name</th>
<th>Basis of Strength</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fenbendazole (UNII: 621BVT9M36) (Fenbendazole - UNII: 621BVT9M36)</td>
<td>Fenbendazole</td>
<td>100 mg in 1 g</td>
</tr>
</tbody>
</table>

## Inactive Ingredients

<table>
<thead>
<tr>
<th>Ingredient Name</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carbomer Homopolymer Type B (Allyl Pentaerythritol Crosslinked) (UNII: HHT01ZNK31)</td>
<td></td>
</tr>
<tr>
<td>Propylene Glycol (UNII: 6DC9Q167V3)</td>
<td></td>
</tr>
<tr>
<td>Glycerin (UNII: PDC6A3C0OX)</td>
<td></td>
</tr>
<tr>
<td>Sorbitol (UNII: 506T60A25R)</td>
<td></td>
</tr>
<tr>
<td>Water (UNII: 059QF0KO0R)</td>
<td></td>
</tr>
<tr>
<td>Sodium Hydroxide (UNII: 55X04QC32I)</td>
<td></td>
</tr>
<tr>
<td>Methylparaben (UNII: A2I8C7HI9T)</td>
<td></td>
</tr>
<tr>
<td>Propylparaben (UNII: Z8IX2SC1OH)</td>
<td></td>
</tr>
</tbody>
</table>

## Product Characteristics

<table>
<thead>
<tr>
<th>Color</th>
<th>Score</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Shape</td>
<td>Size</td>
</tr>
<tr>
<td>APPLE, CINNAMON</td>
<td>Imprint Code</td>
</tr>
</tbody>
</table>

## Packaging

<table>
<thead>
<tr>
<th>#</th>
<th>Item Code</th>
<th>Package Description</th>
<th>Marketing Start Date</th>
<th>Marketing End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>NDC:57926-082-48</td>
<td>1 in 1 CARTON</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td></td>
<td>57 g in 1 SYRINGE, PLASTIC</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

## Marketing Information

<table>
<thead>
<tr>
<th>Marketing Category</th>
<th>Application Number or Monograph Citation</th>
<th>Marketing Start Date</th>
<th>Marketing End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>NADA</td>
<td>NADA120648</td>
<td>07/22/2011</td>
<td></td>
</tr>
</tbody>
</table>

## Labeler

- Schering Corporation (001317601)

## Establishment

<table>
<thead>
<tr>
<th>Name</th>
<th>Address</th>
<th>ID/FEI</th>
<th>Business Operations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intervet Production S.A.</td>
<td></td>
<td>771867553</td>
<td>MANUFACTURE</td>
</tr>
<tr>
<td>Establishment</td>
<td>Name</td>
<td>Address</td>
<td>ID/FEI</td>
</tr>
<tr>
<td>----------------------</td>
<td>-------------------</td>
<td>---------</td>
<td>--------</td>
</tr>
<tr>
<td>DPT Laboratories, Ltd.</td>
<td></td>
<td></td>
<td>832224526</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Establishment</th>
<th>Name</th>
<th>Address</th>
<th>ID/FEI</th>
<th>Business Operations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intervet Mexico S.A. de C.V.</td>
<td></td>
<td></td>
<td>588215863</td>
<td>API MANUFACTURE</td>
</tr>
</tbody>
</table>

Revised: 6/2012

Schering Corporation